XML 21 R6.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Treasury Stock
Beginning of period (in shares) at Jan. 31, 2020   115,830,000        
Beginning of period at Jan. 31, 2020 $ 201,212 $ 122 $ 636,008 $ (360) $ (422,653) $ (11,905)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Exercise of stock options (in shares)   3,064,000        
Exercise of stock options 16,516 $ 3 16,513      
Vested restricted stock units converted to common shares (in shares)   4,358,000        
Vested restricted stock units converted to common shares 0 $ 4 (4)      
Issuance of restricted stock (in shares)   38,000        
Issuance of restricted stock 0          
Issuance of common stock under employee stock purchase plan (in shares)   699,000        
Issuance of common stock under employee stock purchase plan 7,000 $ 1 6,999      
Stock-based compensation 74,417   74,417      
Other comprehensive income 2,782     2,782    
Net loss (94,692)       (94,692)  
End of period (in shares) at Jan. 31, 2021   123,989,000        
End of period at Jan. 31, 2021 207,235 $ 130 733,933 2,422 (517,345) (11,905)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Exercise of stock options (in shares)   2,220,000        
Exercise of stock options 19,197 $ 2 19,195      
Vested restricted stock units converted to common shares (in shares)   4,402,000        
Vested restricted stock units converted to common shares 0 $ 4 (4)      
Issuance of restricted stock (in shares)   15,000        
Issuance of restricted stock 0          
Issuance of common stock under employee stock purchase plan (in shares)   531,000        
Issuance of common stock under employee stock purchase plan 6,485 $ 1 6,484      
Stock-based compensation 74,821   74,821      
Other comprehensive income (2,609)     (2,609)    
Net loss $ (93,259)       (93,259)  
End of period (in shares) at Jan. 31, 2022 131,156,986 131,157,000        
End of period at Jan. 31, 2022 $ 211,870 $ 137 834,429 (187) (610,604) (11,905)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Exercise of stock options (in shares) 259,003 259,000        
Exercise of stock options $ 711 $ 0 711      
Vested restricted stock units converted to common shares (in shares)   3,967,000        
Vested restricted stock units converted to common shares (5,133) $ 4 (5,137)      
Issuance of common stock under employee stock purchase plan (in shares)   796,000        
Issuance of common stock under employee stock purchase plan 3,815 $ 1 3,814      
Stock-based compensation 63,551   63,551      
Repurchase of common stock (in shares)   (13,844,000)        
Repurchase of common stock (77,423)         (77,423)
Other comprehensive income (3,430)     (3,430)    
Net loss $ (65,938)       (65,938)  
End of period (in shares) at Jan. 31, 2023 122,334,515 122,335,000        
End of period at Jan. 31, 2023 $ 128,023 $ 142 $ 897,368 $ (3,617) $ (676,542) $ (89,328)